How Tesamorelin Affects Triglycerides

Tesamorelin reduces triglycerides through GH-mediated lipolysis and visceral fat reduction:

1. Visceral fat mobilisation: Tesamorelin preferentially reduces visceral adipose tissue (VAT), which is the primary source of portal free fatty acid flux to the liver. Reduced visceral fat lowers hepatic triglyceride synthesis.
2. GH-mediated lipolysis: GH promotes lipolysis (fat breakdown) and fatty acid oxidation. Tesamorelin's pulsatile GH stimulation drives fat mobilisation, particularly from visceral depots.
3. Reduced hepatic VLDL production: With less visceral fat delivering FFAs to the liver, hepatic VLDL-triglyceride assembly and secretion decrease.
4. Improved insulin sensitivity at the liver: Visceral fat reduction improves hepatic insulin sensitivity, which further reduces de novo lipogenesis and triglyceride output.

This mechanism is distinct from statins (which primarily lower LDL via HMG-CoA reductase inhibition) and from fibrates (which activate PPAR-alpha to increase triglyceride clearance). Tesamorelin addresses triglycerides through upstream fat reduction rather than downstream metabolic manipulation.

Standard dose (2 mg/day):

• Triglycerides decreased by approximately 50 mg/dL vs. a 9 mg/dL increase in placebo (Falutz et al., 2007)
• Total cholesterol-to-HDL ratio improved by 0.31 vs. worsening by 0.21 in placebo
• Visceral fat reduced by 15.2%
• Effects were observed over 26 weeks of treatment

Context for AAS users:

• Many AAS users have elevated triglycerides from SHBG suppression, lipase alterations, and high-calorie diets
• Tesamorelin's triglyceride-lowering effect is clinically meaningful in this population
• A 50 mg/dL reduction can move an athlete from above-range (200+ mg/dL) back toward normal (under 150 mg/dL)

Timeline: Triglyceride improvement begins within the first month and is well-established by 3-6 months.

Baseline: Full lipid panel (total cholesterol, HDL, LDL, triglycerides) before starting.

During use:

• Lipid panel at 3 months to confirm triglyceride benefit
• Repeat at 6 months and then annually
• Monitor alongside IGF-1 to correlate GH response with lipid changes

Interpretation: If triglycerides are not improving after 3 months of consistent tesamorelin use, verify product authenticity and injection technique.

Maximising the lipid benefit:

• Consistent daily dosing is important; the lipid effects require sustained visceral fat reduction
• Combine with cardiovascular exercise for additive triglyceride-lowering effects
• Dietary omega-3 fatty acids (2-4 g EPA/DHA daily) complement tesamorelin's mechanism

For AAS users with elevated triglycerides:

• Tesamorelin is one of the few peptides that directly addresses a common AAS side effect
• The combination of triglyceride reduction and visceral fat loss makes it particularly relevant during bulking phases when AAS-induced lipid disruption is worst
• It does not replace cardiovascular protective strategies (exercise, diet, and potentially omega-3 or fibrate therapy) but adds a unique GH-mediated component